Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of HR19042 Capsule in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Primary IgA Nephropathy
- Interventions
- Drug: HR19042 capsule
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04887532
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
Phase 3
Completed
- Conditions
- Mixed HyperlipidemiaNon-familial Hypercholesterolemia
- Interventions
- Drug: SHR-1209 ;placebo
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 692
- Registration Number
- NCT04885218
- Locations
- 🇨🇳
Beijing Anzhen hospital, Beijing, Beijing, China
A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04884009
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT04869488
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia
Phase 2
Completed
- Conditions
- Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
- Interventions
- Drug: HR020602 injection
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04867343
- Locations
- 🇨🇳
General Hospital, Tianjin Medical University, Tianjin, Tianjin, China
A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects
Phase 1
- Conditions
- Pain
- Interventions
- Drug: HRS4800 tabletsDrug: placebo
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04862884
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT04862091
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Trial of SHR0410 Injection for the Treatment of Pain After Endoscopic Surgery of the Lower Abdominal
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT04852003
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04850638
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Pyrotinib；Fluconazole
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04850651
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath